C-Peptide

Metabolic

Glucose Regulation

C-peptide is a byproduct released in equal amounts to insulin when the pancreas produces it, so it measures the body's own insulin output independently of any injected insulin. This makes it a clean read on how hard the beta cells are working. A longevity practice uses C-peptide to assess pancreatic function and the degree of insulin demand.

What It Measures

Byproduct of insulin production; measures endogenous insulin output independently of exogenous insulin

Optimal vs. Lab Range

Longevity Optimal

1.0–2.0 ng/mL

Target range for optimal health and longevity based on research.

Standard Lab

0.8–3.1 ng/mL

Population-based reference range from standard labs.

Why It Matters

Elevated C-peptide reflects high endogenous insulin output, which typically points to insulin resistance and beta cell stress, both central to metabolic aging. Because it tracks the pancreas's own production, it can reveal excess insulin demand before glucose values become abnormal. Persistently high output signals the kind of metabolic strain that precedes prediabetes and its downstream cardiovascular and healthspan consequences. On the other end, low C-peptide indicates reduced insulin production, as in type 1 diabetes, late-stage type 2 with beta cell exhaustion, or after pancreatectomy. It is interpreted alongside fasting insulin, fasting glucose, and HOMA-IR.

When Low

Type 1 diabetes, late-stage type 2 (beta cell exhaustion), pancreatectomy

When High

Insulin resistance, insulinoma, beta cell stress

How to Optimize

When C-peptide is high, the priority is reducing insulin resistance so the pancreas is not forced to overproduce insulin, which also helps preserve beta cell function. Time-restricted eating, resistance training, zone 2 cardio, and weight loss all lower insulin demand over time. Because C-peptide interpretation depends on the clinical context, your physician guides whether high or low values need further evaluation. Retesting with fasting insulin and glucose tracks the metabolic trend. Targets and treatment are individualized with your physician; this content is educational and not a substitute for medical advice.

Key Interventions & Linked Compounds

Moderate evidence

Key Interventions

Address insulin resistance

preserve beta cell function

Linked Compounds & Supplements

Berberine

Myo-inositol

NAC

Curated from clinical literature. Individual results vary; consult a qualified clinician before changing a protocol.

Ordering Notes

Specimen

Serum or plasma (venous draw)

Patient prep

No fasting required. Maintain usual diet and medications unless advised.

Recommended cadence

Semi-annual

Reporting unit

Confirm with the performing lab — units vary by region.

Pre-analytic notes

Standardize draw time of day, hydration, and recent exercise. Note any acute illness, supplements, or hormonal therapies on the requisition.

Recommended Follow-Up Actions

1
Confirm the result is reliable
Repeat abnormal values before acting — preferably from the same lab, same time of day, and under consistent prep. Rule out acute illness, recent intense exercise, or medication effects that can shift C-Peptide.
2
Compare against optimal, not just lab range
Use the optimal window above as the target. Lab "normal" is built from the general population and often misses early dysfunction.
3
Pair with related markers
Order a complementary panel covering metabolic, inflammatory, and hormonal context to interpret this marker properly.
4
Discuss interventions with a clinician
Use the interpretation guidance above to frame the conversation. Bring trends, not just one datapoint, to your visit.
5
Re-test on a defined cadence
If a change is implemented, re-measure in 8–12 weeks for fast-moving markers, or 3–6 months for slower ones, to confirm response before escalating.